The role of biomarkers in understanding and targeting adaptive resistance in metastatic colorectal cancer

Metastatic colorectal cancer (mCRC) is characterized by molecular heterogeneity and the development of adaptive resistance to systemic therapies. Biomarkers have become central to understanding resistance biology and guiding treatment selection, spanning established genomic alterations, circulating tumor DNA (ctDNA)-based monitoring, and emerging molecular classifications. Herein, we provide a synthesis of biomarker-driven resistance mechanisms across major therapeutic classes in mCRC, including anti-EGFR, anti-VEGF, BRAF-targeted, KRAS-targeted, HER2-directed, and immunotherapy-based approaches. PubMed/MEDLINE and Google Scholar were searched for relevant literature published through August 2026. Resistance to targeted therapies converges on reactivation of key signaling pathways, particularly MAPK, through genomic and microenvironmental factors. ctDNA represents an important tool for longitudinal assessment of tumor evolution and has demonstrated clinical validity in selected settings, including molecular selection for anti-EGFR rechallenge. Across other therapeutic classes, ctDNA dynamics and resistance profiling are primarily prognostic or investigational, and prospective evidence that ctDNA-guided treatment adaptation improves outcomes remains limited. Emerging biomarkers, including immune-related gene expression patterns, features of the tumor microenvironment, and metabolic adaptations, may improve prediction of therapeutic response. Integration of longitudinal biomarker assessment with ctDNA profiling may enable earlier detection of resistance and more individualized treatment strategies, although the clinical benefit of ctDNA-guided treatment adaptation remains to be established.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-11-14
DOI
https://doi.org/10.1080/14796694.2026.2758043
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The role of biomarkers in understanding and targeting adaptive resistance in metastatic colorectal cancer

John H. Strickler, Cody R. Eslinger, Daniel Ahn, Tanios Bekaii-Saab et al.
Future Oncology
Colorectal Cancer Treatments and Studies
article

The role of biomarkers in understanding and targeting adaptive resistance in metastatic colorectal cancer

John H. Strickler, Cody R. Eslinger, Daniel Ahn, Tanios Bekaii-Saab, Zhaohui Jin
article en

Abstract

Metastatic colorectal cancer (mCRC) is characterized by molecular heterogeneity and the development of adaptive resistance to systemic therapies. Biomarkers have become central to understanding resistance biology and guiding treatment selection, spanning established genomic alterations, circulating tumor DNA (ctDNA)-based monitoring, and emerging molecular classifications. Herein, we provide a synthesis of biomarker-driven resistance mechanisms across major therapeutic classes in mCRC, including anti-EGFR, anti-VEGF, BRAF-targeted, KRAS-targeted, HER2-directed, and immunotherapy-based approaches. PubMed/MEDLINE and Google Scholar were searched for relevant literature published through August 2026. Resistance to targeted therapies converges on reactivation of key signaling pathways, particularly MAPK, through genomic and microenvironmental factors. ctDNA represents an important tool for longitudinal assessment of tumor evolution and has demonstrated clinical validity in selected settings, including molecular selection for anti-EGFR rechallenge. Across other therapeutic classes, ctDNA dynamics and resistance profiling are primarily prognostic or investigational, and prospective evidence that ctDNA-guided treatment adaptation improves outcomes remains limited. Emerging biomarkers, including immune-related gene expression patterns, features of the tumor microenvironment, and metabolic adaptations, may improve prediction of therapeutic response. Integration of longitudinal biomarker assessment with ctDNA profiling may enable earlier detection of resistance and more individualized treatment strategies, although the clinical benefit of ctDNA-guided treatment adaptation remains to be established.

Future Oncology
Mayo Clinic (US)
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon